ICE-R regimen: Difference between revisions
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}R-ICE Regimen; RICE Regimen; Rituximab-Ifosfamide-Carboplatin-Etoposide Regimen ==Overview== {{PAGENAME}} refers to a chemoimm...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemoimmunotherapy regimen consisting of [[rituximab]], [[ifosfamide]], [[carboplatin]] and [[etoposide]] used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63465&ns=NCI_Thesaurus }}</ref> | {{PAGENAME}} refers to a chemoimmunotherapy regimen consisting of [[rituximab]], [[ifosfamide]], [[carboplatin]] and [[etoposide]] used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63465&ns=NCI_Thesaurus }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|I|Ifosfamide}} | {{chemo|I|Ifosfamide}} | ||
{{chemo|C|Carboplatin}} | {{chemo|C|Carboplatin}} | ||
{{chemo|E|Etoposide}} | {{chemo|E|Etoposide}} | ||
==Indications== | ==Indications== | ||
*Relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref> | *Relapsed and refractory [[non-Hodgkin's lymphoma]].<ref name="pmid12736226">{{cite journal| author=Vose J, Sneller V| title=Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. | journal=Ann Oncol | year= 2003 | volume= 14 Suppl 1 | issue= | pages= i17-20 | pmid=12736226 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12736226 }} </ref> | ||
Latest revision as of 13:08, 27 March 2015
|
WikiDoc Resources for ICE-R regimen |
|
Articles |
|---|
|
Most recent articles on ICE-R regimen Most cited articles on ICE-R regimen |
|
Media |
|
Powerpoint slides on ICE-R regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ICE-R regimen at Clinical Trials.gov Trial results on ICE-R regimen Clinical Trials on ICE-R regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ICE-R regimen NICE Guidance on ICE-R regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ICE-R regimen Discussion groups on ICE-R regimen Patient Handouts on ICE-R regimen Directions to Hospitals Treating ICE-R regimen Risk calculators and risk factors for ICE-R regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ICE-R regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:R-ICE Regimen; RICE Regimen; Rituximab-Ifosfamide-Carboplatin-Etoposide Regimen
Overview
ICE-R regimen refers to a chemoimmunotherapy regimen consisting of rituximab, ifosfamide, carboplatin and etoposide used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory non-Hodgkin's lymphoma.[1][2]
Regimen
RRituximab
IIfosfamide
CCarboplatin
EEtoposide
Indications
- Relapsed and refractory non-Hodgkin's lymphoma.[1]
References
- ↑ 1.0 1.1 Vose J, Sneller V (2003). "Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma". Ann Oncol. 14 Suppl 1: i17–20. PMID 12736226.
- ↑ "NCI Thesaurus".